Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. (Q54619617)

1 June 2018

title

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. (English)

1 reference

1 June 2018

author name string

Hao-Wei Teng

1

1 reference

1 June 2018

Hsei-Wei Wang

2

1 reference

1 June 2018

Wei-Ming Chen

3

1 reference

1 June 2018

Ta-Chung Chao

4

1 reference

1 June 2018

Yao-Yu Hsieh

5

1 reference

1 June 2018

Chi-Hsiu Hsih

6

1 reference

1 June 2018

Cheng-Hwai Tzeng

7

1 reference

1 June 2018

Paul Chih-Hsueh Chen

8

1 reference

1 June 2018

Chueh-Chuan Yen

9

1 reference

1 June 2018

publication date

15 January 2011

1 reference

1 June 2018

Journal of Surgical Oncology

published in

1 reference

1 June 2018

volume

103

1 reference

1 June 2018

issue

8

1 reference

1 June 2018

page(s)

773-781

1 reference

1 June 2018

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma

cites work

1 reference

Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy

21 January 2018

1 reference

Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma

21 January 2018

1 reference

Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital

21 January 2018

1 reference

Synovial sarcoma: ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors

21 January 2018

1 reference

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

21 January 2018

1 reference

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

21 January 2018

1 reference

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

21 January 2018

1 reference

Synovial sarcoma outcome following conservation surgery and radiotherapy

21 January 2018

1 reference

Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens

21 January 2018

1 reference

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models

21 January 2018

1 reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

21 January 2018

1 reference

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

PTEN and the PI3-kinase pathway in cancer

21 January 2018

1 reference

EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor

21 January 2018

1 reference

New perspectives for staging and prognosis in soft tissue sarcoma

21 January 2018

1 reference

SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma

21 January 2018

1 reference

SYT-SSX fusion genes and prognosis in synovial sarcoma.

21 January 2018

1 reference

A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients

21 January 2018

1 reference

Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.21852

1 reference

1 June 2018

1 reference

1 June 2018